ESG vs gastric sleeve long-term results is a question increasingly asked by people exploring their weight loss options in the UK. Endoscopic sleeve gastroplasty (ESG) and laparoscopic sleeve gastrectomy (gastric sleeve surgery) both reduce stomach capacity to support sustained weight loss, but they differ significantly in invasiveness, efficacy, safety, and reversibility. This article compares the two procedures across key clinical dimensions — including long-term weight loss outcomes, metabolic benefits, complication profiles, and recovery — drawing on UK guidance from NICE, BOMSS, and the MHRA to help you make an informed decision.

What Are ESG and Gastric Sleeve Surgery?

Gastric sleeve surgery permanently removes 75–80% of the stomach laparoscopically, while ESG is a minimally invasive endoscopic procedure that folds and reduces stomach volume using sutures without removing tissue.

Endoscopic sleeve gastroplasty (ESG) and laparoscopic sleeve gastrectomy (LSG), commonly known as gastric sleeve surgery, are both procedures designed to reduce the functional capacity of the stomach and support significant, sustained weight loss. However, they differ considerably in their approach, invasiveness, and long-term implications.

Gastric sleeve surgery is a well-established bariatric surgical procedure in which approximately 75–80% of the stomach is permanently removed, leaving a narrow, tube-shaped 'sleeve'. This reduces stomach volume, limits food intake, and alters gut hormones — particularly ghrelin, the hunger hormone — which helps suppress appetite. It is performed laparoscopically under general anaesthesia and is irreversible.

Endoscopic sleeve gastroplasty (ESG), by contrast, is a minimally invasive, incision-free procedure performed entirely through the mouth using a flexible endoscope. A suturing device is used to place a series of full-thickness sutures along the greater curvature of the stomach, effectively folding and reducing its volume by around 70–75%. ESG does not involve the removal of any stomach tissue. Early suture removal may be technically possible; however, full anatomical reversal is not guaranteed — tissue remodelling and fibrosis over time mean that complete restoration of the original stomach shape is uncertain, and reversal is rarely undertaken in practice. ESG is typically performed as a day-case or short-stay procedure under sedation or general anaesthesia.

Both procedures are intended for individuals with obesity. In the UK, NHS access to gastric sleeve surgery is governed by NICE criteria (see the final section). ESG is not routinely commissioned on the NHS; NICE has published Interventional Procedures Guidance (IPG) stating that ESG should only be used with special arrangements for clinical governance, informed consent, and audit or research. In practice, ESG is currently available primarily through private providers in the UK. BMI values throughout this article are expressed in kg/m².

Comparing Long-Term Weight Loss Outcomes

Gastric sleeve surgery achieves approximately 25–30% total body weight loss at one year and 60–70% excess weight loss at five years; ESG achieves approximately 15–18% TBWL at one year with greater long-term variability.

When evaluating ESG vs gastric sleeve long-term results, weight loss efficacy is one of the most critical considerations. The evidence base for gastric sleeve surgery is considerably more mature, with robust data spanning over a decade and UK-specific outcomes reported through the National Bariatric Surgical Registry (NBSR) and the British Obesity and Metabolic Surgery Society (BOMSS). Long-term ESG data — beyond five years — remains more limited and is subject to greater variability across centres and patient populations.

Gastric sleeve surgery consistently demonstrates strong outcomes in published studies and registry data:

• Average total body weight loss (TBWL) of approximately 25–30% at one year

• Excess weight loss (EWL) of around 60–70% at five years in many cohorts

• Some weight regain is commonly observed beyond five years; long-term outcomes vary by centre, patient adherence, and follow-up intensity

ESG has shown promising mid-term results in published studies and meta-analyses:

• Average TBWL of approximately 15–18% at one year

• Published five-year data (including a multicentre study reported in Gut, 2022) suggest weight loss can be sustained in a proportion of patients, though with greater variability than surgical cohorts and with TBWL generally lower than after LSG

• TBWL is the preferred metric for cross-procedure comparison, as excess weight loss figures can be influenced by baseline BMI and cohort selection

ESG generally produces less total weight loss than gastric sleeve surgery, and some patients experience more significant weight regain over time. For individuals with a BMI in the 30–40 kg/m² range, ESG may deliver clinically meaningful and durable results, though the possibility of inadequate weight loss or regain — and the option of revision or conversion to a surgical procedure — should be discussed with a specialist team before proceeding.

Patient adherence to dietary and behavioural changes plays a significant role in long-term outcomes for both procedures. Neither intervention is a standalone solution; both require ongoing lifestyle modification, nutritional support, and regular follow-up to optimise and sustain results. Patients should discuss realistic expectations with a specialist bariatric team before making a decision.

Risks, Complications and Safety Profiles

Gastric sleeve carries surgical risks including staple line leak (1–2.5%), GORD, and nutritional deficiencies requiring lifelong supplementation; ESG has a major complication rate under 2% with lower nutritional risk.

Both ESG and gastric sleeve surgery carry procedural risks, though their safety profiles differ meaningfully given the difference in invasiveness. Understanding these risks is essential for informed decision-making.

Gastric sleeve surgery carries the risks associated with major abdominal surgery under general anaesthesia. UK-specific complication and mortality data are reported through the NBSR and BOMSS; risks vary by centre, surgical experience, and individual patient factors. Recognised complications include:

• Staple line leak — a serious complication requiring urgent intervention, reported in approximately 1–2.5% of cases in published series

• Bleeding, infection, and venous thromboembolism (VTE)

• Gastric stricture or stenosis — narrowing of the sleeve, which may require endoscopic dilatation

• Gastro-oesophageal reflux disease (GORD) — a well-documented long-term concern; some patients develop new or worsening reflux post-operatively, which may require proton pump inhibitor (PPI) therapy, investigation for hiatus hernia, or, in refractory cases, conversion to an alternative procedure

• Nutritional deficiencies — particularly in vitamin B12, iron, folate, and vitamin D — requiring lifelong supplementation in line with BOMSS guidance

• Mortality risk is low but present; figures vary by centre and patient risk profile

• Gallstone formation — rapid weight loss increases the risk of gallstones; patients should be advised to seek assessment if they develop symptoms of biliary colic (right upper abdominal pain, particularly after eating)

ESG has a more favourable short-term safety profile:

• Major complication rates are reported at under 2% in large published series

• Risks include perigastric fluid collections, bleeding, and pulmonary complications related to sedation or anaesthesia

• GORD may also occur but appears less frequently than with gastric sleeve

• As no stomach tissue is removed, nutritional risks are lower, though dietary guidance and monitoring are still recommended

• Gallstone risk with rapid weight loss applies to ESG as well, albeit to a lesser degree given the more modest weight loss achieved

Patients and healthcare professionals should report suspected adverse events or device-related incidents via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk). Anyone experiencing symptoms such as severe abdominal pain, persistent vomiting, fever, difficulty swallowing, or signs of biliary colic following either procedure should seek urgent medical attention.

Metabolic and Health Benefits Over Time

Gastric sleeve surgery achieves type 2 diabetes remission in approximately 50–70% of patients at one year; ESG also improves metabolic markers but has a less extensive long-term evidence base.

Beyond weight reduction, both ESG and gastric sleeve surgery offer meaningful metabolic benefits, which are increasingly recognised as central to the value of obesity interventions. These benefits extend to conditions closely associated with excess weight, including type 2 diabetes, hypertension, dyslipidaemia, and obstructive sleep apnoea.

Gastric sleeve surgery has a well-established metabolic impact, supported by systematic reviews and longitudinal cohort studies including sleeve-specific analyses and randomised trials such as STAMPEDE:

• Type 2 diabetes remission — defined in many studies as achieving target HbA1c without glucose-lowering medication — has been reported in approximately 50–70% of patients at one year, with sustained remission in a significant proportion at five years, though rates vary by study definition and patient population

• Significant improvements in blood pressure, cholesterol levels, and HbA1c

• Reduction in cardiovascular risk factors, supported by long-term cohort data

• Improvements in non-alcoholic fatty liver disease (NAFLD) and polycystic ovary syndrome (PCOS)

It should be noted that the Swedish Obese Subjects (SOS) study, frequently cited in bariatric literature, predominantly assessed gastric bypass and banding rather than sleeve gastrectomy specifically; sleeve-specific metabolic data should be drawn from more recent cohort studies and meta-analyses.

ESG also demonstrates metabolic benefits, though the evidence base is less extensive and benefits appear to correlate with the degree of TBWL achieved:

• Studies report improvements in insulin resistance, blood glucose, and lipid profiles

• A 2021 study published in Obesity Surgery noted meaningful reductions in HbA1c and fasting glucose at 12 months

• Longer-term metabolic data for ESG remain limited

Metabolic improvements following bariatric procedures are not solely attributable to weight loss — proposed mechanisms include hormonal changes (including alterations in incretin signalling) and gut microbiome changes, particularly after surgical intervention. For patients with significant metabolic comorbidities, gastric sleeve surgery may offer more robust and durable metabolic benefits. However, ESG remains a clinically relevant option for those seeking improvement in metabolic health with a lower procedural risk profile.

Ongoing monitoring by a GP or specialist is recommended for all patients post-procedure, including regular assessment of HbA1c, lipid profile, blood pressure, and — following sleeve gastrectomy — micronutrient levels in line with BOMSS follow-up guidance.

Reversibility, Recovery and Quality of Life

Gastric sleeve is irreversible with a 1–3 day hospital stay and 6–8 week recovery; ESG recovery takes 1–2 weeks, though full anatomical reversal is not guaranteed due to tissue remodelling.

The differences in reversibility and recovery between ESG and gastric sleeve surgery are significant factors for many patients when weighing their options.

Gastric sleeve surgery involves permanent anatomical change. Once the stomach tissue is removed, the procedure cannot be undone. Recovery typically involves:

• A hospital stay of 1–3 days

• Return to light activities within 2–4 weeks

• Full recovery and return to a normal diet over 6–8 weeks

• Lifelong nutritional supplementation and follow-up in line with BOMSS guidance

ESG, being endoscopic and non-resective, does not involve permanent tissue removal. Early suture removal may be technically feasible; however, full anatomical reversal is not guaranteed due to tissue remodelling over time, and reversal is not routinely offered. Recovery is notably faster:

• Most patients are discharged the same day or after one night

• Return to normal activities within 1–2 weeks

• Dietary progression over 4–6 weeks

In terms of quality of life, both procedures are associated with improvements in physical functioning, self-esteem, and mental wellbeing as weight loss progresses. Gastric sleeve patients may experience more significant dietary restrictions long-term, and GORD can negatively affect quality of life in a subset of patients. ESG patients generally report a smoother early recovery and fewer dietary limitations, though the psychological adjustment to a changed relationship with food applies to both groups.

Patients who have undergone bariatric surgery are typically advised to avoid pregnancy for at least 12–18 months post-operatively, as rapid weight loss during this period may affect foetal development and nutritional status. Contraception should be discussed with a clinician before and after the procedure.

Psychological support and access to a multidisciplinary team — including a dietitian, psychologist, and bariatric nurse — are considered best practice for both procedures and are integral to NHS bariatric pathways. Patients should contact their GP or bariatric team promptly if they experience unexplained weight regain, nutritional symptoms, or psychological difficulties following either procedure.

Which Option Is Right for You? NHS and NICE Guidance

NICE recommends gastric sleeve for adults with BMI ≥40 kg/m² or ≥35 with comorbidities via NHS referral; ESG is not routinely NHS-commissioned and requires discussion with a specialist bariatric team.

Choosing between ESG and gastric sleeve surgery is a highly individual decision that should be made in consultation with a qualified bariatric specialist, taking into account BMI (kg/m²), comorbidities, personal preferences, and access to services.

NICE guidance (CG189: Obesity: identification, assessment and management) recommends bariatric surgery — including gastric sleeve — for adults who meet the following criteria and have engaged with a Tier 3 specialist weight management programme without achieving adequate results:

• A BMI of 40 kg/m² or above, or

• A BMI of 35–39.9 kg/m² with one or more significant obesity-related conditions (e.g., type 2 diabetes, hypertension)

• Adults with recent-onset type 2 diabetes may be considered at a BMI of 30–34.9 kg/m²

• Lower BMI thresholds apply for people from South Asian, Chinese, and other high-risk ethnic backgrounds, in whom obesity-related health risks occur at lower BMI values

• Patients must be fit for anaesthesia and surgery, and must demonstrate commitment to long-term follow-up

Access through the NHS varies by Integrated Care Board (ICB), and waiting times can be lengthy. Patients who meet NICE criteria are encouraged to seek referral through their GP to an NHS bariatric service.

Regarding ESG specifically, NICE has published Interventional Procedures Guidance (IPG) stating that ESG should only be used with special arrangements for clinical governance, informed consent, and audit or research. ESG is not routinely commissioned on the NHS and is predominantly offered through private providers in the UK.

Key considerations when discussing options with your clinician:

• BMI and comorbidity profile — higher BMI or significant metabolic disease may favour surgical intervention

• Ethnicity — lower BMI thresholds may apply; discuss with your clinician

• Preference for a less permanent procedure — ESG may appeal to those seeking an option without permanent anatomical change, though full reversal is not guaranteed

• Risk tolerance — ESG carries a lower procedural risk but generally produces less weight loss

• Access and cost — NHS eligibility, ICB commissioning policies, private funding, and aftercare availability

• Aftercare — both procedures require long-term follow-up; ensure any private provider offers a full multidisciplinary team

Anyone experiencing unexplained weight gain, nutritional symptoms, or psychological difficulties following either procedure should contact their GP promptly. Suspected adverse events or device-related incidents should be reported via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk).

Not sure if this is normal? Chat with one of our pharmacists →

Frequently Asked Questions